| Literature DB >> 21367769 |
Alan J Forster1, Jim R Worthington, Steven Hawken, Michael Bourke, Fraser Rubens, Kaveh Shojania, Carl van Walraven.
Abstract
BACKGROUND To improve patient safety, organisations must systematically measure avoidable harms. Clinical surveillance-consisting of prospective case finding and peer review-could improve identification of adverse events (AEs), preventable AEs and potential AEs. The authors sought to describe and compare findings of clinical surveillance on four clinical services in an academic hospital. METHODS Clinical surveillance was performed by a nurse observer who monitored patients for prespecified clinical events and collected standard information about each event. A multidisciplinary, peer-review committee rated causation for each event. Events were subsequently classified in terms of severity and type. RESULTS The authors monitored 1406 patients during their admission to four hospital services: Cardiac Surgery Intensive Care (n=226), Intensive Care (n=211), General Internal Medicine (n=453) and Obstetrics (n=516). The authors detected 245 AEs during 9300 patient days of observation (2.6 AEs per 100 patient days). 88 AEs (33%) were preventable. The proportion of patients experiencing at least one AE, preventable AE or potential AE was 13.7%, 6.1% and 5.3%, respectively. AE risk varied between services, ranging from 1.4% of Obstetrics to 11% of Internal Medicine and Intensive Care patients experiencing at least one preventable AE. The proportion of patients experiencing AEs resulting in permanent disability or death varied between services: ranging from 0.2% on Obstetrics to 4.9% on Cardiac Surgery Intensive Care. No services shared the most frequent AE type. CONCLUSIONS Using clinical surveillance, the authors identified a high risk of AE and significant variation in AE risks and subtypes between services. These findings suggest that institutions will need to evaluate service-specific safety problems to set priorities and design improvement strategies.Entities:
Mesh:
Year: 2011 PMID: 21367769 PMCID: PMC3161499 DOI: 10.1136/bmjqs.2010.048694
Source DB: PubMed Journal: BMJ Qual Saf ISSN: 2044-5415 Impact factor: 7.035
Figure 1Prospective clinical surveillance overview.
Patients participating in the surveillance development cohort study
| Cardiac surgery | Intensive care | Internal medicine | Obstetrics | |||||
| Patients | N=226 | N=211 | N=453 | N=516 | ||||
| Age, median (IQR) | 70 (61 to 76) | 66 (54 to 75) | 74 (61 to 84) | 30 (26 to 33) | ||||
| Length of stay, median (IQR) | 2.1 (1.1 to 5.0) | 4.8 (2.6 to 9.3) | 8 (5 to 14) | 2.4 (1.9 to 3.1) | ||||
| Female | 68 (30%) | 79 (37%) | 225 (50%) | 516 (100%) | ||||
| Charlson index | ||||||||
| 0 | 69 (31%) | 63 (30%) | 78 (17%) | – | ||||
| 1 | 113 (50%) | 94 (45%) | 165 (36%) | – | ||||
| 2 | 37 (16%) | 40 (19%) | 103 (23%) | – | ||||
| 3 | 7 (3%) | 14 (7%) | 107 (24%) | – | ||||
| Diabetes | ||||||||
| Mild | 61 (27%) | 19 (9%) | 63 (14%) | – | ||||
| Severe | 19 (8%) | 9 (4%) | 76 (17%) | – | ||||
| Cancer | ||||||||
| Local | 0 (0%) | 23 (11%) | 61 (13%) | – | ||||
| Metastatic | 0 (0%) | 3 (1%) | 20 (4%) | – | ||||
| Congestive heart failure | 32 (14%) | 17 (8%) | 95 (21%) | – | ||||
| Chronic obstructive pulmonary disease | 31 (14%) | 33 (16%) | 84 (19%) | – | ||||
| Renal disease | 29 (13%) | 17 (8%) | 82 (18%) | – | ||||
| Admit indication (top 10) | CABG | 123 (54%) | Neurological disease | 39 (19%) | Infection | 122 (27%) | Labour | 324 (63%) |
| Other | 28 (12%) | Elective surgery | 34 (16%) | Fluid, electrolyte | 51 (11%) | Induction | 87 (17%) | |
| AVR | 26 (12%) | Respiratory failure | 30 (14%) | Pulmonary | 45 (10%) | Elective Caesarean section | 56 (11%) | |
| AVR+CABG | 23 (10%) | Other | 25 (12%) | Gastrointestinal | 34 (8%) | Ruptured membranes | 34 (7%) | |
| MVR | 12 (5%) | Trauma | 24 (11%) | Vascular | 34 (8%) | Pregnancy-induced hypertension | 10 (2%) | |
| MVR+CABG | 6 (3%) | Sepsis syndrome | 23 (11%) | Congestive heart failure | 28 (6%) | Maternal illness | 3 (1%) | |
| Multiple valves | 5 (2%) | Emergency surgery | 19 (9%) | Cognitive | 24 (5%) | Antepartum bleeding | 1 (0%) | |
| Multiple valves+CABG | 3 (1%) | Cardiogenic shock | 7 (3%) | Social | 16 (4%) | |||
| Shock other | 6 (3%) | Haematological | 14 (3%) | |||||
| Dysrhythmia | 3 (1%) | Diabetes mellitus complications | 11 (2%) | |||||
Diabetes was classified as mild or severe based on the presence of end organ damage.
AVR, aortic valve replacement; CABG, coronary artery bypass graft; MVR, mitral valve replacement.
Adverse event (AE) risk and rate
| Overall | Cardiac surgery | Intensive care | Internal medicine | Obstetrics | p value (χ2 test) | |
| Risk | ||||||
| Patients observed | 1406 | 226 | 211 | 453 | 516 | |
| Patients with at least one AE | 192 (13.7%) | 45 (19.9%) | 52 (24.6%) | 75 (16.6%) | 20 (3.9%) | <0.001 |
| Patients with at least one preventable AE | 86 (6.1%) | 8 (3.5%) | 23 (10.9%) | 48 (10.6%) | 7 (1.4%) | <0.001 |
| Patients with at least one potential AE | 75 (5.3%) | 6 (2.7%) | 17 (8.1%) | 40 (8.8%) | 12 (2.3%) | <0.001 |
| Rate | ||||||
| Days of observation | 9300 | 1234 | 1592 | 5026 | 1448 | |
| AE rate (per 100 patient days) | 245 (2.6) | 62 (5.0) | 72 (4.5) | 89 (1.8) | 22 (1.5) | <0.001 |
| Preventable AE rate (per 100 patient days) | 88 (0.9) | 8 (0.6) | 23 (1.4) | 50 (1.0) | 7 (0.5) | 0.03 |
| Potential AE rate (per 100 patient days) | 81 (0.9) | 7 (0.6) | 20 (1.3) | 42 (0.8) | 12 (0.8) | 0.24 |
Risk was calculated as the number of patients with at least one event divided by the total number of patients observed.
Rate reported as events per 100 patient days, which was calculated as the number of events divided by the number of patient days of observation multiplied by 100.
Adverse event severity and type
| Overall N (%) | Cardiac surgery N (%) | Intensive care N (%) | Medicine N (%) | Obstetrics N (%) | p Value (χ2 test) | |
| Total | 245 (100) | 62 (100) | 72 (100) | 89 (100) | 22 (100) | |
| Severity | <0.001 | |||||
| Lab/physiological | 36 (14.7) | 2 (3.2) | 10 (13.9) | 23 (25.8) | 1 (4.6) | |
| Symptoms | 75 (30.7) | 9 (14.5) | 18 (25.0) | 38 (42.7) | 10 (45.5) | |
| Temporary | 112 (45.9) | 40 (64.5) | 36 (50.0) | 26 (29.2) | 10 (45.5) | |
| Permanent | 16 (6.6) | 8 (12.9) | 7 (9.7) | 0 (0.0) | 1 (4.6) | |
| Death | 6 (2.5) | 3 (4.8) | 1 (1.4) | 2 (2.3) | 0 (0.0) | |
| Type | <0.001 | |||||
| Procedural complication | 42 (17.14) | 7 (11.3) | 17 (23.6) | 11 (12.4) | 7 (31.8) | |
| Infection | 37 (15.1) | 12 (19.4) | 18 (25.0) | 7 (7.9) | 0 (0.0) | |
| Adverse drug event | 46 (18.8) | 4 (6.5) | 9 (12.5) | 27 (30.3) | 6 (27.3) | |
| Therapeutic error | 49 (20.0) | 5 (8.1) | 14 (19.4) | 22 (24.7) | 8 (36.4) | |
| Surgical complication | 37 (15.1) | 29 (46.8) | 7 (9.7) | 0 (0.0) | 1 (4.6) | |
| Diagnostic error | 10 (4.1) | 3 (4.8) | 4 (5.6) | 3 (3.4) | 0 (0.0) | |
| Falls | 10 (4.1) | 0 (0.0) | 0 (0.0) | 10 (11.2) | 0 (0.0) | |
| System problem | 11 (4.5) | 2 (3.2) | 3 (4.2) | 6 (6.7) | 0 (0.0) | |
| Pressure ulcer | 3 (1.2) | 0 (0.0) | 0 (0.0) | 3 (3.4) | 0 (0.0) | |